Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia
Completed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3
2003-08-01
The purpose of the study is to compare the pharmacokinetic parameters (blood concentrations)
of i.m. paliperidone palmitate after administration in 2 different injection sites (deltoid
or gluteal).
Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia
Completed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2
2003-10-01
The purpose of this study is to determine the efficacy (how well the drug works), safety, and
side effects of paliperidone palmitate injection compared to placebo in the treatment of the
symptoms of schizophrenia in adults. The placebo used in this study was a nutritional
substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.
Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia
Completed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3
2004-01-01
The purpose of this trial is to determine if paliperidone ER is an effective treatment for
adults with schizophrenia.
Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
Completed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3
2004-03-01
The primary objective of the double blind phase of this study is to evaluate the efficacy and
safety of 3 fixed dosages of paliperidone ER (6, 9, and 12 mg/day) compared with placebo in
adult patients with schizophrenia.
Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
Completed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3
2004-04-01
The primary objective of the double-blind phase of this study is to evaluate the efficacy and
safety of 3 fixed dosages of paliperidone ER (3, 9, and 15 mg/day) compared with placebo in
adult patients with schizophrenia
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
